Complete Filing Data
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Stockholders Equity of -$375.5 thousand for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cordyceps Sunshine Biotech Holdings Co., Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Operating Income Loss | -$183.9K | $227.8K | -$415.1K | -$119.4K |
| Operating Expenses | $717.7K | $538.6K | $454.7K | $119.4K |
| Net Income Loss | -$226.3K | $751.6K | -$720.1K | -$491.0K |
| Comprehensive Income Net Of Tax | -$223.7K | $799.5K | -$675.5K | -$495.4K |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $2.5K | $47.9K | $44.6K | -$4.4K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$191.3K | $190.8K | -$415.1K | -$119.4K |
| Income Loss From Continuing Operations | -$226.3K | $169.3K | -$415.1K | -$119.4K |
| Revenues | $1.3M | $882.5K | $53.3K | $879.3K |
| Income Loss From Discontinued Operations Net Of Tax | $582.3K | -$305.0K | -$371.6K | |
| Gross Profit | $533.8K | $766.4K | $39.6K | -$176.2K |
| Cost Of Revenue | $719.7K | $116.1K | $13.7K | $1.1M |
| Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax | $2.5K | $47.9K | $44.6K | -$4.4K |
| Nonoperating Income Expense | -$7.4K | -$37.0K | $10.00 | $7.00 |
| Income Loss From Continuing Operations Per Diluted Share | $0.00 | $0.00 | $0.00 | -$1.19 |
| Income Loss From Continuing Operations Per Basic Share | $0.00 | $0.00 | $0.00 | -$1.19 |
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | $0.01 | $0.00 | -$3.72 | |
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | $0.01 | $0.00 | -$3.72 | |
| Discontinued Operation Income Loss From Discontinued Operation Before Income Tax | -$282.8K | -$305.0K | -$371.6K | |
| Other Nonoperating Income Expense | $5.3K | $2.8K | -$4.9K | -$1.1K |
| Research And Development Expense | $118.4K | $25.1K | ||
| Other General And Administrative Expense | $717.7K | $538.6K | $336.2K | $13.8K |
| Income Tax Expense Benefit | $35.0K | $21.5K | $792.00 | $351.00 |
| General And Administrative Expense | $572.6K | $273.7K | ||
| Interest Income Expense Nonoperating Net | -$17.1K | -$39.8K | $10.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Stockholders Equity | -$375.5K | -$151.8K | -$951.3K | -$275.8K | -$12.8K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $37.3K | $23.1K | $6.6K | $99.5K | $294.00 |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $37.3K | $23.1K | $16.1K | $99.7K | $294.00 |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $14.2K | $7.0K | -$83.6K | $99.4K | |
| Retained Earnings Accumulated Deficit | -$699.2K | -$473.0K | -$1.2M | -$504.5K | -$13.5K |
| Property Plant And Equipment Net | $3.9M | $2.8M | $75.5K | $1.7M | $1.7M |
| Operating Lease Liability Noncurrent | $12.6K | $106.4K | $121.1K | $203.3K | $11.1K |
| Operating Lease Liability Current | $87.0K | $90.1K | $57.1K | $66.2K | $4.7K |
| Liabilities Current | $5.0M | $3.0M | $2.5M | $2.9M | $2.4M |
| Liabilities And Stockholders Equity | $4.6M | $3.4M | $2.1M | $3.3M | $2.8M |
| Liabilities | $5.0M | $3.5M | $3.1M | $3.5M | $2.8M |
| Common Stock Value | $11.1K | $11.1K | $11.1K | $10.0K | $10.0K |
| Cash Provided By Used In Operating Activities Discontinued Operations | $37.9K | $73.5K | -$224.7K | ||
| Cash Provided By Used In Investing Activities Discontinued Operations | -$333.00 | -$475.00 | -$10.8K | ||
| Cash Provided By Used In Financing Activities Discontinued Operations | -$46.9K | -$63.5K | $246.2K | ||
| Cash And Cash Equivalents At Carrying Value | $37.3K | $23.1K | $6.6K | $99.7K | $294.00 |
| Assets Current | $601.6K | $327.2K | $501.6K | $1.1M | $949.0K |
| Assets | $4.6M | $3.4M | $2.1M | $3.3M | $2.8M |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $91.3K | $88.8K | $40.8K | -$3.7K | $664.00 |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations | $63.00 | $9.5K | $197.00 | ||
| Operating Lease Right Of Use Asset | $99.3K | $195.8K | $178.2K | ||
| Long Term Debt Noncurrent | $431.1K | $414.0K | |||
| Operating Lease Right Of Use Asset Amortization Expense | $86.2K | $56.7K | $4.9K | ||
| Other Receivables Net Current | $120.3K | $9.5K | |||
| Operating Lease Expense | $90.6K | $81.2K | $56.7K | ||
| Accrued Liabilities Current | $32.4K | $26.9K | $62.8K | $56.4K | $29.5K |
| Accounts Payable Current | $276.1K | $185.4K | $751.1K | $111.7K | $123.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Financing Cash Flow * | -$32.2K | $245.8K | $574.5K | |
| Investing Cash Flow * | -$305.6K | -$319.8K | -$475.00 | -$110.8K |
| Operating Cash Flow * | $312.0K | $359.7K | -$321.4K | -$365.4K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.8K | -$692.00 | -$7.5K | $1.1K |
| Increase Decrease In Operating Lease Liability | -$91.0K | -$80.5K | -$56.7K | -$4.9K |
| Proceeds From Related Party Debt | $14.6K | $309.3K | $178.6K | |
| Payments To Acquire Property Plant And Equipment | $349.2K | $319.5K | $475.00 | $100.0K |
| Increase Decrease In Other Receivables | -$2.3K | $2.4K | $10.5K | |
| Increase Decrease In Prepaid Supplies | $4.2K | $7.4K | ||
| Increase Decrease In Inventories | $192.6K | -$48.8K | $166.7K | |
| Increase Decrease In Due To Related Parties | $193.4K | $18.8K | -$10.8K | |
| Increase Decrease In Accrued Liabilities | $7.4K | $26.5K | $10.9K | $25.8K |
| Proceeds From Repayments Of Related Party Debt | -$151.4K | -$240.7K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 111.1M | 111.1M | 104.4M | 100.0K | |
| Weighted Average Number Of Diluted Shares Outstanding | 111.1M | 111.1M | 104.4M | 100.0K | |
| Earnings Per Share Diluted | $0.00 | $0.01 | $-0.01 | $0.00 | |
| Earnings Per Share Basic | $0.00 | $0.01 | $-0.01 | $0.00 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 111.1M | 111.1M | 111.1M | 111.1M | 111.1M |
| Common Stock Shares Issued | 111.1M | 111.1M | 111.1M | 111.1M | 111.1M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Professional Fees | $238.1K | $165.2K | $80.6K | |
| Additional Paid In Capital | $221.3K | $221.3K | $221.3K | |
| Depreciation | $407.3K | $56.8K | $24.5K | $420.00 |
| Labor And Related Expense | $109.3K | $47.8K | $80.2K | |
| Interest Income Other | $7.00 | $10.00 | $7.00 |
Most recent annual filing with the SEC: June 13, 2025
Data sourced from SEC EDGAR public filings as of August 7, 2026.